Login to Your Account

Santaris Signs $200M LNA Oncology Pact With Enzon

By Cormac Sheridan

Friday, July 28, 2006
Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals Inc., which is worth well in excess of $200 million in up-front fees and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription